Etoposide (VP16) in the treatment of multisystem Langerhans cell histiocytosis (histiocytosis X).
Etoposide (VP16) in the treatment of multisystem Langerhans cell histiocytosis (histiocytosis X).
复制标题
依托泊苷 (VP16) 治疗多系统朗格汉斯细胞组织细胞增多症（组织细胞增多症 X）。
DOI：
10.1002/mpo.2950170205
复制
发表时间：
1989
期刊：
影响因子：
--
通讯作者：
E. Yeomans
中科院分区：
文献类型：
--
作者：
V. Broadbent;J. Pritchard;E. Yeomans
10例朗格汉斯细胞组织细胞增生症（组织细胞增生症X）患儿接受了依托泊苷（VP 16）治疗。9回答在一种情况下，部分尿崩症暂时逆转。无严重毒性。依托泊苷应认真考虑作为治疗LCH患者的类固醇治疗的毒性/效益比是不可接受的高。
Ten children with Langerhans cell histiocytosis (histiocytosis X) either resistant to or intolerant of corticosteroids received etoposide (VP16). Nine responded. In one instance, partial diabetes insipidus was temporarily reversed. There was no major toxicity. Etoposide should be seriously considered as therapy for patients with LCH in whom the toxicity/benefit ratio of steroid therapy is unacceptably high.